Literature DB >> 12435689

Mutagenically separated PCR assay for rapid detection of M41L and K70R zidovudine resistance mutations in CRF01_AE (subtype E) human immunodeficiency virus type 1.

Lay Myint1, Koya Ariyoshi, Hua Yan, Alexander J Frater, Wattana Auwanit, Panita Pathipvanith, Kaneo Yamada, Masakazu Matsuda, Tomoko Chiba, Kazunori Fujita, Myra McClure, Jonathan N Weber, Wataru Sugiura.   

Abstract

A rapid zidovudine (ZDV) resistance genotypic assay was developed based on the mutagenically separated PCR (MS-PCR) technique to detect two ZDV-resistant mutations, M41L and K70R in CRF01_AE (subtype E). Endpoint dilution analysis revealed that the newly constructed MS-PCR assay could successfully detect three to nine copies of human immunodeficiency virus type 1 template RNA. The test against wild-type and mutant template mixtures in different ratios demonstrated that the assay could detect 10% minor population, at least. Fifty-one subtype E clinical samples were analyzed by the newly constructed MS-PCR assay and direct nucleotide sequencing. The concordance of the two assays was 92 and 100% in codons 41 and 70, respectively. The MS-PCR assay is a rapid, simple, and inexpensive assay that is highly sensitive in detecting mutant targets, including minor populations. Thus, it could be used as a powerful tool for epidemiological surveillance of drug-resistant mutations in developing countries.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12435689      PMCID: PMC132767          DOI: 10.1128/AAC.46.12.3861-3868.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

1.  Application of HIV-1 genotypic-resistance testing prevents the evolution of further resistance mutations in heavily pretreated patients.

Authors:  B Zöllner; H H Feucht; L Weitner; A Adam; M Schröter; P Schäfer; R Laufs
Journal:  J Clin Virol       Date:  2001-04       Impact factor: 3.168

2.  Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group.

Authors:  N Shaffer; R Chuachoowong; P A Mock; C Bhadrakom; W Siriwasin; N L Young; T Chotpitayasunondh; S Chearskul; A Roongpisuthipong; P Chinayon; J Karon; T D Mastro; R J Simonds
Journal:  Lancet       Date:  1999-03-06       Impact factor: 79.321

3.  Simple detection of point mutations associated with HIV-1 drug resistance.

Authors:  A J Frater; C C Chaput; S Beddows; J N Weber; M O McClure
Journal:  J Virol Methods       Date:  2001-04       Impact factor: 2.014

4.  Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.

Authors:  G R Kaufmann; K Suzuki; P Cunningham; M Mukaide; M Kondo; M Imai; J Zaunders; D A Cooper
Journal:  AIDS Res Hum Retroviruses       Date:  2001-04-10       Impact factor: 2.205

5.  Augmentation of human immunodeficiency virus type 1 subtype E (CRF01_AE) multiple-drug resistance by insertion of a foreign 11-amino-acid fragment into the reverse transcriptase.

Authors:  H Sato; Y Tomita; K Ebisawa; A Hachiya; K Shibamura; T Shiino; R Yang; M Tatsumi; K Gushi; H Umeyama; S Oka; Y Takebe; Y Nagai
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

6.  Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy.

Authors:  D R Kuritzkes; D Shugarts; M Bakhtiari; D Poticha; J Johnson; M Rubin; T R Gingeras; M Kennedy; J J Eron
Journal:  J Acquir Immune Defic Syndr       Date:  2000-01-01       Impact factor: 3.731

7.  Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy.

Authors:  J Servais; C Lambert; E Fontaine; J M Plesséria; I Robert; V Arendt; T Staub; F Schneider; R Hemmer; G Burtonboy; J C Schmit
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

8.  A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients.

Authors:  C Ungsedhapand; E D Kroon; S Suwanagool; K Ruxrungtham; N Yimsuan; A Sonjai; S Ubolyam; S Buranapraditkun; S Tiengrim; N Pakker; C Kunanusont; J M Lange; D A Cooper; P Phanuphak
Journal:  J Acquir Immune Defic Syndr       Date:  2001-06-01       Impact factor: 3.731

Review 9.  Update on HIV/AIDS in Thailand.

Authors:  K Ruxrungtham; P Phanuphak
Journal:  J Med Assoc Thai       Date:  2001-06

10.  Comparison of capillary electrophoresis sequencing with the new CEQ 2000 DNA Analysis System to conventional gel based systems for HIV drug resistance analysis.

Authors:  P Merel; I Pellegrin; I Garrigue; A Caumont; M H Schrive; V Birac; P Bonot; H Fleury
Journal:  J Virol Methods       Date:  2001-10       Impact factor: 2.014

View more
  3 in total

1.  Novel enzyme-linked minisequence assay for genotypic analysis of human immunodeficiency virus type 1 drug resistance.

Authors:  Wataru Sugiura; Kazunori Shimada; Masakazu Matsuda; Tomoko Chiba; Lay Myint; Aiko Okano; Kaneo Yamada
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

2.  SMARThivPack: a complexity free and cost effective "three tests" combo kit model for improving HIV patients monitoring standards in resource poor settings.

Authors:  Aboubakar Yari; Frederic S Passo; Jean-Pierre Hounyet
Journal:  Bioinformation       Date:  2007-12-01

3.  Sequencing-based detection of low-frequency human immunodeficiency virus type 1 drug-resistant mutants by an RNA/DNA heteroduplex generator-tracking assay.

Authors:  Amit Kapoor; Morris Jones; R W Shafer; Soo-Yon Rhee; Powel Kazanjian; Eric L Delwart
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.